tbuckley/cabot-search huggingface dataset:
Mass spectrometry confirmation that clinically important peanut protein allergens are present in household dust
Authors: Helen A. Brough, Elizabeth Naomi Clare Mills, Kerry Richards, Gideon Lack, Philip E. Johnson
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
The influence of TDM on achieving busulfan target exposure and related determinants, in both children and adults who underwent an allogeneic hematopoietic cell transplantation
Authors: J. Boss, J. Langenhorst, A. Lalmohamed, P. van der Linden, J.J. Boelens, E. Van Maarseveen
Journal: Annals of Oncology (2019)
Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
Authors: D.J. Slamon, P. Neven, S. Chia, P.A. Fasching, M. De Laurentiis, S.-A. Im, K. Petrakova, G.V. Bianchi, F.J. Esteva, M. Martin, A. Nusch, G.S. Sonke, L. De la Cruz-Merino, J.T. Beck, X. Pivot, M. Sondhi, Y. Wang, A. Chakravartty, K. Rodriguez-Lorenc, G. Jerusalem
Journal: Annals of Oncology (2019)
Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: A matched cohort study
Authors: A.H. Boekhout, A. Rogiers, K. Jozwiak, M.J. Boers-Sonderen, A.J.M. van den Eertwegh, G.A. Hospers, J.W. de Groot, M.J.B. Aarts, E. Kapiteijn, A.J. Ten Tije, D. Piersma, G. Vreugdenhil, A.A.M. Van der Veldt, K.P.M. Suijkerbuijk, E.A. Rozeman, B. Neyns, K.J. Janssen, L.V. van de Poll-Franse, C.U. Blank
Journal: Annals of Oncology (2019)
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Authors: J.C.F. Quintanilha, A. Racioppi, J. Wang, S. Denning, A.S. Etheridge, C.E. Peña, D.J. Crona, D. Lin, F. Innocenti
Journal: Annals of Oncology (2019)
Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
Authors: J.H. Jeong, C. Yoo, K.-P. Kim, H.-M. Chang, B.-Y. Ryoo
Journal: Annals of Oncology (2019)
Anti-tumor activity of novel nuclear export inhibitors (NEIs) in multiple murine leukemia models
Authors: WenQing Yang, Sarah Mutka, Shannon Ward, Hong Fu, Yaoquan Liu, Yong Li, Robert Johnson, Pieter Timmermans, Sumati Murli
Journal: Cancer Research (2008)

5688  CRM1 is an essential protein required to export a set of ‘cargo’ proteins which bear a leucine-rich nuclear export sequence (NES) from the nucleus to the cytoplasm. Examples of cancer-related proteins bearing CRM1-dependent NESs include p53, BCR-Abl, and FOXO-3a. Nuclear sequestration of these CRM1 ‘cargo’ proteins upon inhibition of CRM1 can lead to cell growth inhibition in normal cells or apoptosis in cancer cells. The identification of CRM1 as a novel target in cancer came from the study of Leptomycin B (LMB) and its analogs. These molecules are potent cytotoxic agents which belong to a group of polyketide natural products known as nuclear export inhibitors (NEIs). LMB and its analogs covalently bind to the nuclear exportin CRM1 and thereby inhibit its ability to shuttle cargo proteins to the cytoplasm. The development of LMB was limited by the significant toxicity observed in previous studies (Newlands, et al., 1996, Br. J. Can., 74: 648-649). We have recently developed a series of NEI analogs with significantly improved biological and pharmacological properties over LMB. Upon examination of the activity of these molecules in leukemia cell lines, we found that NEIs were very potent in vitro in ALL (Molt-4, CCRF-CEM, Jurkat) and AML (MV-4-11) cell lines. Exposure to NEIs led to a rapid and dramatic induction of multiple markers of apoptosis (caspases, Annexin V binding). Based on these results, we examined the activity of two NEI analogs, KOS-1815 and KOS-2464, in murine leukemia xenograft models. Both of these drugs, when dosed on a weekly schedule, significantly inhibited the growth of MV-4-11 (T/C = ~22% for KOS-2464 and ~26% for KOS-1815) and Molt-4 (T/C = ~38% for KOS-2464 and ~29% for KOS-1815) xenografts. In addition, a single administration of KOS-2464 or KOS-1815 induced regression of large (>1000 mm3) CCRF-CEM xenografts. KOS-2464 was very well-tolerated at efficacious doses in all of these leukemia models, while KOS-1815 induced a ~5 to 10% transient body weight loss upon dosing. Finally, we established a Molt-4 orthotopic leukemia model in mice. Weekly dosing of KOS-1815 and KOS-2464 for three weeks, beginning eight days after cancer cell implantation, doubled survival of these leukemic mice. Median survival increased from 25 days for the control group to 50+ days for the drug-treated groups (56 days for KOS-2464 and 50 days for KOS-1815). Studies are ongoing to gain further insight into the mechanism by which these molecules exert their activity in leukemia models. Taken together, the current study shows that KOS-2464, our lead NEI analog, with its novel mechanism of action and wide therapeutic window, has significant potential as a novel anti-cancer agent, especially for the treatment of leukemia.
Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events
Authors: Z.W. Veitch, D. Shepshelovich, C. Gallagher, L. Wang, A.A. Razak, A. Spreafico, P. Bedard, L.L. Siu, L. Minasian, A.R. Hansen
Journal: Annals of Oncology (2019)
Proteomic profiling identifies molecular basis of adverse event to BPM31510 exposure: Rationale for comprehensive molecular pharmacodynamics (PD) in phase I clinical trial design
Authors: V. Subbiah, E. Granger, M. Kiebish, R. Zinner, D.S. Hong, G. Miller, L. Zhang, V. Vemulapalli, L. Rodrigues, N. Narain, R. Sarangarajan
Journal: Annals of Oncology (2019)
Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Authors: W. Xu, M. Puligandla, N.B. Haas, K.T. Flaherty, R.G. Uzzo, V. Sabbisetti, J.J. Dutcher, R.S. DiPaola, R.S. Bhatt
Journal: Annals of Oncology (2019)
Neoadjuvant olaparib monotherapy in primary triple negative breast cancer
Authors: H.P. Eikesdal, S. Yndestad, E.S. Blix, S. Lundgren, G. Vagstad, H. Espelid, B. Gilje, E.A. Janssen, J. Geisler, T. Aas, H. Aase, S. Knappskog, P.E. Lønning
Journal: Annals of Oncology (2019)
Effect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry
Authors: K. Schlack, M. Boegemann, M. Woike, G. Krekeler, T. Fischer, L. Bergmann, M. Rink, M. Schmid, A. Strauss
Journal: Annals of Oncology (2019)
Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours
Authors: M.O. Butler, V. Sotov, S. Saibil, L. Bonilla, S. Boross-Harmer, M. Fyrsta, D. Gray, M. Nelles, M. Le, D. Lemiashkova, D. Liu, A.G. Sacher, A. Trang, K. Vakili, B. Van As, E. Scheid, L. Nguyen, S. Takahashi, S. Tanaka, N. Hirano
Journal: Annals of Oncology (2019)
THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)
Authors: M.E. Milla, J.L. Ptacin, L. Ma, C.E. Caffaro, H.R. Aerni, K.M. San Jose, M.J. Pena, R.W. Herman, Y. Pavlova, D.B. Chen, T.K. Ismaili, S. Li, J. Nguyen, N. Singh, L.K. Shawver, L.K. Koriazova, I.B. Joseph
Journal: Annals of Oncology (2019)
Metastatic cancer whole-exome sequencing in daily practice
Authors: M. Réda, C. Richard, J. Niogret, J.-D. Fumet, A. Bertaut, J. Blanc, C. Truntzer, I. Desmoulins, S. Ladoire, L. Bengrine-Lefevre, N. Isambert, A. Hervieu, C. Lepage, P. Foucher, C. Borg, L. Arnould, S. Nambot, L. Faivre, R. Boidot, F. Ghiringhelli
Journal: Annals of Oncology (2019)
Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Authors: M.C.T. van Zeijl, M W J M Wouters, A.J.M. van den Eertwegh, L.C. de Wreede, M.J.B. Aarts, A.C.J. van Akkooi, F W P J Van den Berkmortel, J.W. de Groot, M.J. Boers-Sonderen, J.J.M. van der Hoeven, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. Ten Tije, A.A.M. Van der Veldt, G. Vreugdenhil, J B A G Haanen
Journal: Annals of Oncology (2019)
PALAESTRA: A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Authors: D. Borg, J. Sundberg, E. Brun, E. Kjellén, K. Petersson, M. Hermansson, J. Johansson, J. Eberhard, A. Johnsson
Journal: Annals of Oncology (2019)
Plasma Adenosine Levels Increase in Patients With Chronic Heart Failure
Authors: HiroharuFunaya, MasafumiKitakaze, KoichiNode, TetsuoMinamino, KazuoKomamura, MasatsuguHori
Journal: Circulation (1997)

Background Adenosine is believed to be cardioprotective; however, it has not been elucidated whether the plasma adenosine level is increased in chronic heart failure. Methods and Results Seventy-one patients attending a specialized heart failure clinic during a 6-month period were grouped according to the cause of chronic heart failure and the New York Heart Association function class. There were 40 patients with chronic heart failure due to ischemic heart diseases and 31 patients with valvular heart diseases and dilated cardiomyopathy. Control subjects consisted of 64 healthy laboratory staff members and patients without chronic heart failure. We found that the plasma adenosine levels were increased in patients with ischemic and nonischemic heart failure (218±23 and 211±21 nmol/L, respectively, versus 62±3 nmol/L for healthy subjects) and that the extent of increases in adenosine levels correlated well with the severity of chronic heart failure. Conclusions We conclude that adenosine levels in the system...
Abstract 3253: Mobilization of Stem Cells is a Predictor of LVEF Improvement After Intracoronary Infusion of Bone Marrow-derived Selected CD34+CXCR4+Cells in Patients With Acute MI
Authors: Wojciech Wojakowski, Maciej Kazmierski, Marek Krol, Krzysztof Milewski, Joanna Ciosek, Magda Kucia, Ewa Zuba-Surma, Pawel Buszman, Andrzej Ochala, Piotr Klimeczek, Mieczyslaw Pasowicz, Wojciech Rychlik, Radoslaw Parma, Marcin Majka, Mariusz Z Ratajczak, Michal Tendera
Journal: Circulation (2009)
Syed Fateh Shah Abbasi
Authors: N S Abbasi
Journal: BMJ (2003)

Former general practitioner Bradford, West Yorkshire (b Gujrat, Pakistan, 1921; q Dow Medical College, Karachi, 1966), died from necrotising pancreatitis and multiple organ failure on 17 July 2003.

Brought up in Karachi, Pakistan, he married while he was still in his early teens and left school after the equivalent of O levels to work. From selling teabags on a bicycle to working as a fumigation inspector on aeroplanes, he struggled to make ends meet. It was only when his boss said that he did not have the education or experience to be promoted that my father went back to school. By the time he began his medical studies my parents had four children and by the time he qualified they had 10. He moved to the United Kingdom in 1969, eventually settling down as a general practitioner and building up his practice from one patient to around 3400 patients by the time he retired in 1991. He leaves a wife, Anwar, and 10 children.
Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study
Authors: M. Pagano, R. Gnoni, C. Bonelli, F. Zanelli, M.C. Garassino, G.L. Ceresoli, G. Pasello, M. Tiseo, H.J. Soto Parra, F. Grosso, P.A. Zucali, M. Larocca, F. Torricelli, A. Ciarrocchi, C. Pinto
Journal: Annals of Oncology (2019)
First line pembrolizumab for NSCLC with PD-L1 TPS &gt; 50% in a first French real life cohort
Authors: K. Amrane, M. Geier, R. Corre, G. Léveiller, G. Florence, R. Lamy, J.L. Bizec, E. Goarant, G. Robinet, S. Ulrike, G. Quere, C. Bernier, R. Descourt
Journal: Annals of Oncology (2019)
EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
Authors: C.J. Hoimes, J.E. Rosenberg, S. Srinivas, D.P. Petrylak, M. Milowsky, J.R. Merchan, M.A. Bilen, S. Gupta, A.-S. Carret, N. Yuan, A. Melhem-Bertrandt, T. Flaig
Journal: Annals of Oncology (2019)
Ablation of Immunoproteasome β5i Subunit Suppresses Hypertensive Retinopathy by Blocking ATRAP Degradation in Mice
Authors: Shuai Wang, Jing Li, Tong Wang, Jie Bai, Yun-Long Zhang, Qiu-Yue Lin, Jing-min Li, Qi Zhao, Shu-Bin Guo, Hui-Hua Li
Journal: Molecular Therapy (2019)

Inflammation is associated with retinal diseases. Our recent data demonstrate that immunoproteasome catalytic subunit β2i contributes to angiotensin II (Ang II)-induced retinopathy in mice. Here, we investigated the role of another catalytic subunit β5i in regulating retinopathy and its underlying mechanisms. We induced a murine model of retinopathy by infusing Ang II (3,000 ng/kg/min) for 3 weeks into wild-type (WT) mice, β5i-knockout (KO) mice, or WT mice injected with either adenovirus-expressing β5i (Ad-β5i) or angiotensin II type 1 receptor (AT1R)-associated protein (Ad-ATRAP), which inhibits AT1R. The β5i expression and chymotrypsin-like activity were most significantly elevated in Ang II-infused retinas and serum from patients with hypertensive retinopathy. Moreover, Ang II infusion-induced retinopathy was markedly attenuated in β5i-KO mice but aggravated in Ad-β5i-injected mice. Accordingly, β5i KO markedly restored Ang II-induced downregulation of ATRAP and activation of AT1R downstream mediators, which was further enhanced in Ad-β5i-injected mice. Interestingly, overexpression of ATRAP significantly abrogated Ang II-induced retinopathy in Ad-β5i-injected mice. This study found that β5i promoted Ang II-induced retinopathy by promoting ATRAP degradation and activation of AT1R-mediated signals.
Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial
Authors: R. Garcia-Carbonero, M. Gil Martín, R. Alvarez Gallego, T. Macarulla Mercade, M.C. Riesco Martinez, C. Guillen-Ponce, N. Vidal, F.X. Real, R. Moreno, V. Maliandi, A. Mato-Berciano, M. Bazan-Peregrino, G. Capella, R. Alemany, E. Blasi, C. Blasco, M. Cascallo, R. Salazar
Journal: Annals of Oncology (2019)
Early on-treatment vs pre-treatment tumour transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Authors: S. Pernas, S. Goel, N.T. Johnson, B.T. Harrison, J.L. Guerriero, J. Hu, G. Winship, A. Sokolov, M.M. Regan, E.A. Mittendorf, B. Overmoyer
Journal: Annals of Oncology (2019)
Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study
Authors: M. Valladares-Ayerbes, P. García-Alfonso, J Muñoz Luengo, P Pimentel Cáceres, J.M. Viéitez, J.J. Cruz-Hernández, M. Llanos, C Garcia Girón, L. Cirera, A Lloansí Vila
Journal: Annals of Oncology (2019)
Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Authors: S C F A Huijberts, L. Wang, S. Wilgenhof, H. Rosing, B. Nuijen, J.H. Beijnen, R Leite de Oliveira, R. Bernards, J.H.M. Schellens
Journal: Annals of Oncology (2019)
Clinical benefit and response rate in early phase clinical trials: First report from a single-institution study
Authors: A. Marra, E. Ferraro, M. Repetto, E. Nicolò, P. D’Amico, E. Marrucci, I. Caramella, P. Tarantino, S. Morganti, G. Viale, D. Trapani, G. Curigliano
Journal: Annals of Oncology (2019)
Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Authors: Y. Drew, B. Kaufman, S. Banerjee, A. Lortholary, S.H. Hong, Y.H. Park, S. Zimmermann, P. Roxburgh, M. Ferguson, R.H. Alvarez, S. Domchek, C. Gresty, H.K. Angell, V Rocher Ros, K. Meyer, M. Lanasa, P. Herbolsheimer, M. de Jonge
Journal: Annals of Oncology (2019)
Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor pembrolizumab and trastuzumab in preclinical models
Authors: N. Maurea, V. Quagliariello, M. Passariello, C. Coppola, D. Rea, A. Barbieri, C. De Lorenzo, G. Monti, M. De Laurentiis, P.A. Ascierto, G. Botti
Journal: Annals of Oncology (2019)
Bioactive glass coatings on metallic implants for biomedical applications
Authors: Joy-anne N. Oliver, Yingchao Su, Xiaonan Lu, Po-Hsuen Kuo, Jincheng Du, Donghui Zhu
Journal: Bioactive Materials (2019)

Metallic implant materials possess adequate mechanical properties such as strength, elastic modulus, and ductility for long term support and stability in vivo. Traditional metallic biomaterials, including stainless steels, cobalt-chromium alloys, and titanium and its alloys, have been the gold standards for load-bearing implant materials in hard tissue applications in the past decades. Biodegradable metals including iron, magnesium, and zinc have also emerged as novel biodegradable implant materials with different in vivo degradation rates. However, they do not possess good bioactivity and other biological functions. Bioactive glasses have been widely used as coating materials on the metallic implants to improve their integration with the host tissue and overall biological performances. The present review provides a detailed overview of the benefits and issues of metal alloys when used as biomedical implants and how they are improved by bioactive glass-based coatings for biomedical applications.
Air pollution and cardiovascular disease: car sick
Authors: Mark R Miller, David E Newby
Journal: Cardiovascular Research (2019)

Abstract The cardiovascular effects of inhaled particle matter (PM) are responsible for a substantial morbidity and mortality attributed to air pollution. Ultrafine particles, like those in diesel exhaust emissions, are a major source of nanoparticles in urban environments, and it is these particles that have the capacity to induce the most significant health effects. Research has shown that diesel exhaust exposure can have many detrimental effects on the cardiovascular system both acutely and chronically. This review provides an overview of the cardiovascular effects on PM in air pollution, with an emphasis on ultrafine particles in vehicle exhaust. We consider the biological mechanisms underlying these cardiovascular effects of PM and postulate that cardiovascular dysfunction may be implicated in the effects of PM in other organ systems. The employment of multiple strategies to tackle air pollution, and especially ultrafine particles from vehicles, is likely to be accompanied by improvements in cardiovascular health.
Diseases of the Eye. A Manual for the Practitioner.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Development of a novel clinical and radiological risk score to predict septic complications in patients with obstructive uropathy
Authors: C. Bebi, I. Fulgheri, M.G. Spinelli, M. Turetti, E. Lievore, F. Ripa, L. Rocchini, E. De Lorenzis, G. Albo, M. D’Amico, G. Carrafiello, E. Montanari, L. Boeri
Journal: European Urology (2021)
Abstract 4397: Tak-1 inhibition re-sensitizes cancer cells to TNFα
Authors: Scott Scarneo, Madeline Sell, Juliane Totzke, David Carlson, Phillip Hughes, Tim Haystead
Journal: Cancer Research (2018)

Abstract Identifying new pharmaceutical targets in cancer has been a long lasting goal of academia. Complex genomic changes coupled with a cancer cell's ability to adapt make tumors particularly difficult to target. To this end, we have identified the TAK1 kinase in the TNFα pathway as a potential mediator of cell survival or apoptosis. Here we evaluate the apoptotic effects of a novel TAK1 inhibitor, Takinib. The selectivity of Takinib was established with an IC50 of 9nm for TAK1, followed by an IC50 for IRAK4 and IRAK1 at 120nm and 390nm respectively. Treatment of MDA-MB-231 cells with Takinib on its own is not sufficient to induce consequential cell death. However, combination therapy with TNFα induces caspase 3/7 activity and subsequent cell death in a dose-dependent manner. Genetic knock out of TAK1 expression in MDA-MB-231 cells with the CRISPR/Cas9 system significantly sensitized previous resistant cells to TNFα. Furthermore, we have shown that activation of human THP-1 cells with LPS is sufficient to produce TNFα levels necessary to facilitate Takinib mediated cell death, indicating that potential immunotherapy applications may be possible. Together these findings support the idea that TAK1 may be an effective target in the TNFα pathway, shifting the cellular mechanisms from pro survival to pro apoptosis. Citation Format: Scott Scarneo, Madeline Sell, Juliane Totzke, David Carlson, Phillip Hughes, Tim Haystead. Tak-1 inhibition re-sensitizes cancer cells to TNFα [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4397.
Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins
Authors: Samir Softic, Jesse G. Meyer, Guo-Xiao Wang, Manoj K. Gupta, Thiago M. Batista, Hans P.M.M. Lauritzen, Shiho Fujisaka, Dolors Serra, Laura Herrero, Jennifer Willoughby, Kevin Fitzgerald, Olga Ilkayeva, Christopher B. Newgard, Bradford W. Gibson, Birgit Schilling, David E. Cohen, C. Ronald Kahn
Journal: Cell Metabolism (2019)
Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
Authors: A. Ocaña, JIL-M Chacón, L. Calvo, A. Antón, M. Mansutti, E. Alba, A. Lluch, A. Lahuerta, G. Bisagni, B. Bermejo, V. Semiglazov, M. Thill, A. Chan, S. Morales, J. Albanell, J. Herranz, I Tusquets Trias Bes, P. Valagussa, M. Chiesa, L. Gianni
Journal: Annals of Oncology (2019)
Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Authors: Y. Sunakawa, Y. Takahashi, E. Inoue, Y. Sakamoto, R. Kawabata, H. Yabusaki, J. Matsuyama, A. Ishiguro, M. Takahashi, Y. Akamaru, Y. Kito, A. Makiyama, H. Yasui, H. Kawakami, T.E. Nakajima, K. Muro, R. Matoba, W. Ichikawa, M. Fujii
Journal: Annals of Oncology (2019)
Health-related quality of life issues of patients affected by desmoid-type fibromatosis: Experiences from two countries
Authors: M.J. Timbergen, W.T. van der Graaf, D.J. Grünhagen, E. Younger, S. Sleijfer, A. Dunlop, L. Dean, C. Verhoef, L.V. van de Poll-Franse, O. Husson
Journal: Annals of Oncology (2019)